John Kang

@johnkang64

Science lover + Scottish fold enthusiast

Vrijeme pridruživanja: veljača 2016.

Tweetovi

Blokirali ste korisnika/cu @johnkang64

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @johnkang64

  1. proslijedio/la je Tweet
    24. sij

    The anti-cancer efficacy and specificity of magrolimab (formerly known as 5F9), our antibody versus , involves tipping the balance between the “eat me” and “don’t eat me” signals received by macrophages when they encounter a potential target cell.

    Poništi
  2. 3. velj

    A thoughtful piece by from on how will empower next-generation cell & gene therapies

    Poništi
  3. proslijedio/la je Tweet
    3. velj

    How much does it cost to bootstrap a gene therapy startup? Not too much if you're Jim Wilson, per Passage Bio's $125M IPO filing -

    Poništi
  4. proslijedio/la je Tweet

    Crazy fact: Cutting-edge disease cures powered by gene therapy and CRISPR still rely on a toxic drug from the 1950s. I wrote about efforts to fix that problem with new, safer bone marrow conditioning regimens. Featuring

    Poništi
  5. proslijedio/la je Tweet
    15. sij

    Perks of having an HDMZ SF office? Avoiding all the traffic. P.S. the outfit coordination in the second was unintentional but perfect 😉

    Poništi
  6. proslijedio/la je Tweet
    9. sij
    , , i još njih 3
    Poništi
  7. proslijedio/la je Tweet
    8. sij

    I'm happy to announce that I'll be presenting our latest updates on therapies at at the JP Morgan conference, Wednesday, January 15, 2020 @ 11 AM in the Elizabethan D room at Westin St. Francis! !

    Poništi
  8. proslijedio/la je Tweet
    18. pro 2019.

    Nature has often evolved redundant systems to achieve any outcome This can be why cancer drugs struggle to remain effective But it can also be used by researchers to attempt an end-run around a clinical challenge like, in this case, sickle cell anemia

    Poništi
  9. proslijedio/la je Tweet
    18. pro 2019.

    Added a new name to my list of local companies developing beta thalassemia drugs — has partnered up with Global Blood Therapeutics to develop a drug in a deal with $20M upfront and $355M in research funds/milestones

    Poništi
  10. proslijedio/la je Tweet
    9. pro 2019.

    . identifies repressor of fetal gene, possible target for disease Tell , knocking down NFIX increases γ-globin mRNA, detectable fetal hemoglobin in 100% of cells

    Poništi
  11. proslijedio/la je Tweet

    Closing question from : If you are as successful as you hope to be, what do you want the first paragraph of your Wikipedia entry to say in 20 years? Wilson: "That I was the Johnny Appleseed of gene therapy."

    Prikaži ovu nit
    Poništi
  12. proslijedio/la je Tweet

    Big news from and this morning about their CTX001 CRISPR/Cas9 therapy for sickle cell disease + beta-thalassemia. I covered the science of this therapy for back in 2018. Goal is to break BCL11A and boost fetal hemoglobin:

    Poništi
  13. proslijedio/la je Tweet
    19. stu 2019.

    CRISPR stocks close out the day strongly positive: +17% +10% +8% and pre-conditioning focused biotechs, too: +16% +12% +7%

    Poništi
  14. proslijedio/la je Tweet
    14. stu 2019.
    Poništi
  15. proslijedio/la je Tweet
    12. stu 2019.

    V. interesting deal this morning between and to develop antibody-based conditioning for stem-cell based gene therapies like Zynteglo. Current conditioning uses chemo or radiation to prepare bone marrow for engraftment, which isn't ideal.

    Prikaži ovu nit
    Poništi
  16. proslijedio/la je Tweet
    6. stu 2019.

    AML, safety data for magrolimab help Forty Seven shares regain lost ground

    Poništi
  17. proslijedio/la je Tweet
    5. stu 2019.

    Excited to announce the publication of the abstract for our poster presentation at on 11/9 describing our preclinical efficacy data for SENTI-101, a novel allogeneic cell product.

    Poništi
  18. proslijedio/la je Tweet
    10. lis 2019.

    Check out our CEO and co-founder 's TEDMED Talk about biological engineering, released today!

    Poništi
  19. proslijedio/la je Tweet
    2. lis 2019.

    Our CEO and co-founder, , presented today at ARM's Cell & Gene Meeting on the Mesa to share our company's story and the rapid progress our team has made in the field of gene circuit therapies. Connect with and Curt Herberts at this week's conference.

    Poništi
  20. proslijedio/la je Tweet
    23. lis 2019.
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·